Zacks Research Upgrades Collegium Pharmaceutical (NASDAQ:COLL) to Strong-Buy

Collegium Pharmaceutical (NASDAQ:COLL) was upgraded by analysts at Zacks Research from a “hold” rating to a “strong-buy” rating in a report released on Monday,Zacks.com reports.

Several other research firms have also issued reports on COLL. Weiss Ratings lowered shares of Collegium Pharmaceutical from a “buy (b-)” rating to a “hold (c+)” rating in a research note on Thursday, March 5th. Needham & Company LLC reissued a “buy” rating and set a $56.00 price target (up from $54.00) on shares of Collegium Pharmaceutical in a research report on Thursday, March 19th. Truist Financial upgraded shares of Collegium Pharmaceutical to a “strong-buy” rating in a report on Monday, June 15th. Wall Street Zen raised shares of Collegium Pharmaceutical from a “buy” rating to a “strong-buy” rating in a research report on Saturday, May 9th. Finally, HC Wainwright reiterated a “buy” rating and issued a $60.00 price objective on shares of Collegium Pharmaceutical in a research note on Friday, March 20th. Two analysts have rated the stock with a Strong Buy rating, three have assigned a Buy rating and one has given a Hold rating to the stock. Based on data from MarketBeat.com, the company presently has an average rating of “Buy” and an average price target of $57.50.

Collegium Pharmaceutical Stock Up 0.6%

Shares of NASDAQ:COLL opened at $36.20 on Monday. The stock has a market cap of $1.17 billion, a price-to-earnings ratio of 17.75 and a beta of 0.74. The company has a quick ratio of 1.62, a current ratio of 1.71 and a debt-to-equity ratio of 2.47. Collegium Pharmaceutical has a 12-month low of $29.19 and a 12-month high of $50.79. The business’s 50 day moving average is $34.17 and its 200 day moving average is $39.45.

Collegium Pharmaceutical (NASDAQ:COLL) last announced its quarterly earnings results on Thursday, May 7th. The specialty pharmaceutical company reported $1.76 earnings per share (EPS) for the quarter, topping the consensus estimate of $1.52 by $0.24. The business had revenue of $193.52 million during the quarter, compared to the consensus estimate of $184.47 million. Collegium Pharmaceutical had a return on equity of 95.18% and a net margin of 9.41%.Collegium Pharmaceutical’s revenue was up 8.9% compared to the same quarter last year. During the same quarter in the prior year, the company posted $1.49 earnings per share. On average, sell-side analysts forecast that Collegium Pharmaceutical will post 6.76 earnings per share for the current fiscal year.

Institutional Trading of Collegium Pharmaceutical

Several hedge funds have recently made changes to their positions in the company. Vident Advisory LLC grew its stake in shares of Collegium Pharmaceutical by 1.9% during the 3rd quarter. Vident Advisory LLC now owns 15,466 shares of the specialty pharmaceutical company’s stock worth $541,000 after acquiring an additional 281 shares during the period. Quadrant Capital Group LLC raised its stake in Collegium Pharmaceutical by 4.2% in the 4th quarter. Quadrant Capital Group LLC now owns 6,996 shares of the specialty pharmaceutical company’s stock valued at $324,000 after acquiring an additional 282 shares during the period. GAMMA Investing LLC raised its stake in Collegium Pharmaceutical by 9.6% in the 4th quarter. GAMMA Investing LLC now owns 3,262 shares of the specialty pharmaceutical company’s stock valued at $151,000 after acquiring an additional 285 shares during the period. Atom Investors LP lifted its holdings in Collegium Pharmaceutical by 5.0% during the fourth quarter. Atom Investors LP now owns 6,124 shares of the specialty pharmaceutical company’s stock valued at $284,000 after purchasing an additional 294 shares during the last quarter. Finally, Mirae Asset Global Investments Co. Ltd. lifted its holdings in Collegium Pharmaceutical by 26.1% during the fourth quarter. Mirae Asset Global Investments Co. Ltd. now owns 1,536 shares of the specialty pharmaceutical company’s stock valued at $71,000 after purchasing an additional 318 shares during the last quarter.

Collegium Pharmaceutical Company Profile

Collegium Pharmaceutical, Inc is a specialty pharmaceutical company focused on the development, manufacture and commercialization of products for pain management and opioid dependence. The company’s core expertise lies in its DETERx microsphere technology, a platform designed to provide extended-release delivery of active pharmaceutical ingredients while deterring manipulation for unintended routes of abuse.

The company’s principal marketed products include Xtampza® ER (extended-release oxycodone), which received approval from the U.S.